Nimotuzumab Dosing and Outcomes in Locally Advanced Head and Neck Cancer
Madam — A flat dose of 200 mg is approved for nimotuzumab in head and neck cancer [1]. However, doses up to 400 mg are used in pancreatic cancer [2]. This analysis was carried out to determine whether an increment in nimotuzumab dose according to body weight or body surface area is associated with impro ved outcomes. This was a post-hoc analysis of a phase III randomised study carried out in locally advanced head and neck cancer [1]. Of 536 patients enrolled in the study, 268 patients randomised on cisplatin–radical radiation with a nimotuzumab 200 mg flat dose were selected for this analysis.
Source: Clinical Oncology - Category: Radiology Authors: A. Joshi, V.M. Patil, V. Noronha, A. Abhyankar, N. Menon, K. Prabhash Tags: Letter Source Type: research
More News: Cancer | Cancer & Oncology | Head and Neck Cancer | Men | Pancreas | Pancreatic Cancer | Radiology | Study